Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06178588 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 24, 2026 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 22 to confirmed 15 · Primary completion date: Nov 1, 2025 to Mar 1, 2026 · Site details revisedv3 Show 3 more changesShow less
    • Enrollment target: estimated 22 to confirmed 15
    • Primary completion date: Nov 1, 2025 to Mar 1, 2026
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 31, 2023 to Feb 1, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 31, 2023 to Feb 1, 2024
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well sacituzumab govitecan works in treating patients with cholangiocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced), that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a toxic agent, called SN-38. HRS7 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them.
Trial Details
NCT Number NCT06178588
Lead Sponsor University of Kansas Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov